ALMS · Insider Trading
Alumis Inc. Common Stock
Every open-market purchase and sale reported by ALMS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Form 4 Filings
50
most recent
Open-Market Buys
16
code P
Sales
6
code S
Reporting Insiders
24
current holders
ALMS — Recent Form 4 Transactions (latest 2026-09-09)
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Srinivas Akkaraju | Director | MIXED | +890,590 | +$9.71M |
| 2026-08-05 | Sanam Pangali | Chief Legal Officer | Sell | −1,364 | −$35.97K |
| 2026-08-05 | Roy C. Hardiman | Chief Business & Strategy Ofcr | Sell | −2,692 | −$70.99K |
| 2026-08-05 | John R. Schroer | Chief Financial Officer | Sell | −3,282 | −$86.55K |
| 2026-08-05 | Jorn Drappa | Chief Medical Officer | Sell | −2,447 | −$64.53K |
| 2026-08-05 | Mark Christopher Bradley | Chief Development Officer | Sell | −2,572 | −$67.82K |
| 2026-08-05 | David M Goldstein | Chief Scientific Officer | Sell | −2,596 | −$68.46K |
| 2026-07-08 | Sanam Pangali | Chief Legal Officer | MIXED | — | −$114.70K |
| 2026-07-02 | Srinivas Akkaraju | Director | A | +3,553 | — |
| 2026-07-02 | Zhengbin Yao | Director | A | +3,553 | — |
| 2026-07-02 | Sapna Srivastava | Director | A | +3,553 | — |
| 2026-07-02 | Patrick Machado | Director | A | +3,553 | — |
| 2026-07-02 | Lynn A. Tetrault | Director | A | +3,553 | — |
| 2026-05-27 | Jorn Drappa | Chief Medical Officer | M | +26,852 | +$178.65K |
| 2026-04-03 | James B. Tananbaum | Director | J | −495,984 | — |
| 2026-04-03 | Foresite Labs, LLC | 10%+ Owner | J | −991,968 | — |
| 2026-04-03 | Foresite Capital Opportunity Fund V, L.P. | 10%+ Owner | J | −4,463,856 | — |
| 2026-01-28 | Martin Babler | President, CEO and Chairman | A | +745,875 deriv. | — |
| 2026-01-28 | Mark Christopher Bradley | Chief Development Officer | A | +190,225 deriv. | — |
| 2026-01-28 | Roy C. Hardiman | Chief Business & Strategy Ofcr | A | +190,875 deriv. | — |
| 2026-01-28 | John R. Schroer | Chief Financial Officer | A | +202,225 deriv. | — |
| 2026-01-28 | Jorn Drappa | Chief Medical Officer | A | +221,450 deriv. | — |
| 2026-01-28 | David M Goldstein | Chief Scientific Officer | A | +216,675 deriv. | — |
| 2026-01-28 | Sanam Pangali | Chief Legal Officer | A | +186,200 deriv. | — |
| 2026-01-13 | Srinivas Akkaraju | Director | Buy | +588,235 | +$10.00M |
| 2026-01-12 | James B. Tananbaum | Director | Buy | +411,764 | +$7.00M |
| 2026-01-12 | Foresite Labs, LLC | 10%+ Owner | Buy | +823,528 | +$14.00M |
| 2026-01-12 | Foresite Capital Fund V, L.P. | 10%+ Owner | Buy | +3,705,876 | +$63.00M |
| 2025-12-09 | Srinivas Akkaraju | Director | Buy | +186,377 | +$1.83M |
| 2025-12-04 | Srinivas Akkaraju | Director | Buy | +262,027 | +$2.04M |
| 2025-12-01 | Srinivas Akkaraju | Director | Buy | +173,589 | +$1.31M |
| 2025-11-25 | Foresite Labs, LLC | 10%+ Owner | Buy | +144,424 | +$1.07M |
| 2025-11-25 | James B. Tananbaum | Director | Buy | +72,212 | +$532.92K |
| 2025-11-25 | Foresite Labs Fund I, L.P. | 10%+ Owner | Buy | +649,908 | +$4.80M |
| 2025-11-24 | Srinivas Akkaraju | Director | Buy | +125,743 | +$905.35K |
| 2025-11-19 | Srinivas Akkaraju | Director | Buy | +241,338 | +$1.53M |
| 2025-11-19 | James B. Tananbaum | Director | Buy | +507,874 | +$3.09M |
| 2025-11-19 | Foresite Labs Affiliates 2021, LLC | 10%+ Owner | Buy | +1,015,748 | +$6.19M |
| 2025-11-19 | Foresite Capital Opportunity Management V, LLC | 10%+ Owner | Buy | +4,570,866 | +$27.85M |
| 2025-11-17 | Srinivas Akkaraju | Director | Buy | +276,179 | +$1.45M |
| 2025-08-01 | Patrick Machado | Director | A | +49,800 deriv. | — |
| 2025-08-01 | Sapna Srivastava | Director | A | +49,800 deriv. | — |
| 2025-08-01 | Lynn A. Tetrault | Director | A | +49,800 deriv. | — |
| 2025-08-01 | Zhengbin Yao | Director | A | +49,800 deriv. | — |
| 2025-08-01 | Srinivas Akkaraju | Director | A | +49,800 deriv. | — |
| 2025-07-31 | Jorn Drappa | Chief Medical Officer | A | +25,450 | — |
| 2025-07-31 | Martin Babler | President, CEO and Chairman | A | — | — |
| 2025-07-31 | John R. Schroer | Chief Financial Officer | A | +28,000 | — |
| 2025-07-31 | Derrick Richardson | SVP, People and Culture | A | +42,800 | — |
| 2025-07-31 | Mark Christopher Bradley | Chief Development Officer | A | +26,750 | — |
ALMS — Current Insider Holders
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David E. Goel | Director | 15,139,707 | $98.56M |
| Srinivas Akkaraju | Director | 4,667,288 | $30.38M |
| James B. Tananbaum | Director | 4,247,670 | $27.65M |
| Foresite Labs Fund I, L.P. | 10%+ Owner | 2,614,215 | $17.02M |
| Foresite Labs Affiliates 2021, LLC | 10%+ Owner | 2,542,003 | $16.55M |
| Foresite Capital Opportunity Management V, LLC | 10%+ Owner | 2,542,003 | $16.55M |
| Foresite Labs, LLC | 10%+ Owner | 1,960,337 | $12.76M |
| Foresite Capital Opportunity Fund V, L.P. | 10%+ Owner | 1,960,337 | $12.76M |
| Foresite Capital Fund VI LP | 10%+ Owner | 1,176,470 | $7.66M |
| Foresite Capital Fund V, L.P. | 10%+ Owner | 1,176,470 | $7.66M |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | 214,163 | $1.39M |
| Martin Babler | President, CEO and Chairman | 109,454 | $712.55K |
| Mark Christopher Bradley | Chief Development Officer | 68,559 | $446.32K |
| Jorn Drappa | Chief Medical Officer | 56,892 | $370.37K |
| Derrick Richardson | SVP, People and Culture | 42,800 | $278.63K |
| David M Goldstein | Chief Scientific Officer | 39,964 | $260.17K |
| Sara Klein | Chief Legal Officer | 33,796 | $220.01K |
| Zhengbin Yao | Director | 27,082 | $176.30K |
| John R. Schroer | Chief Financial Officer | 24,718 | $160.91K |
| Alan Colowick | Director | 16,104 | $104.84K |
| Patrick Machado | Director | 10,617 | $69.12K |
| Sanam Pangali | Chief Legal Officer | 9,747 | $63.45K |
| Lynn A. Tetrault | Director | 3,553 | $23.13K |
| Sapna Srivastava | Director | 3,553 | $23.13K |
ALMS Insider Trading FAQ
Who are the insiders at ALMS?
24 officers, directors and 10%+ beneficial owners currently report holdings in ALMS via SEC Form 4.
Are ALMS insiders buying or selling?
Across the 50 most recent Form 4 filings for ALMS, 16 were open-market purchases (code P) and 6 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is ALMS insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent ALMS filing is dated 2026-09-09.
How to read Form 4 activity
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALMS quote page; the site-wide leaderboard is on the insider transactions hub.
More on ALMS
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.